下一代肿瘤不可知靶点即将出现
Next-generation tumor-agnostic targets on the horizon.
肿瘤不可知药物开发将肿瘤学重新聚焦于共享的分子依赖性而非组织来源,从而能够针对跨肿瘤的罕见可操作驱动因素进行高效开发。
英文原题:Engineering Study on Targeted Therapy of Osteosarcoma Using Tripterine Loaded Polydopamine Mesoporous Microspheres Combined with Photothermal Therapy.
Engineering Study on Targeted Therapy of Osteosarcoma Using Tripterine Loaded Polydopamine Mesoporous Microspheres Combined with Photothermal Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
MPDA-PEG-CLT 显著提高了雷公藤红素的靶向递送效率,促进骨肉瘤细胞的线粒体凋亡,与光热治疗协同清除肿瘤,并改善病灶的骨组织微环境。
骨肉瘤因复发率高、易转移和预后差而面临重大临床挑战。雷公藤红素(CLT)具有抗肿瘤、免疫调节和骨生成调控作用,已受到广泛关注。开发靶向CLT递送系统对于实现精准释药、整合光热治疗、重塑肿瘤微环境并改善骨肉瘤术后治疗和修复至关重要。
采用乳液诱导界面组装法合成介孔聚多巴胺-聚乙二醇(MPDA-PEG)纳米球,并负载雷公藤红素,制备靶向递送系统MPDA-PEG-CLT。表征纳米球理化性质,并通过体内外实验评估MPDA-PEG-CLT用于骨肉瘤药物-光热协同治疗的疗效。
MPDA-PEG-CLT载药量约为14%;在808 nm近红外光照射下,光热转换效率为37.6%,可促进雷公藤红素释放。该系统诱导骨肉瘤细胞凋亡,促进骨髓间充质干细胞(BMSC)分化并改善病灶微环境,从而在小鼠中有效消融肿瘤。
MPDA-PEG-CLT显著提高雷公藤红素的靶向递送效率,促进骨肉瘤细胞线粒体凋亡,并与光热治疗协同消除肿瘤、改善病灶骨组织微环境。该系统为骨肉瘤术后治疗和修复提供了有前景的策略。
Osteosarcoma poses significant clinical challenges due to its high recurrence, metastatic potential, and poor prognosis. Celastrol (CLT), known for its antitumor, immunomodulatory, and osteogenic regulatory properties, has garnered substantial interest. Developing a targeted CLT delivery system is critical to enable precise drug release, integrate photothermal therapy, remodel the tumor microenvironment, and improve post-surgical treatment and repair in osteosarcoma.
Using emulsion-induced interface assembly, we synthesized mesoporous polydopamine-polyethylene glycol (MPDA-PEG) nanospheres and loaded them with celastrol to fabricate the targeted system MPDA-PEG-CLT. We characterized the nanospheres' physicochemical properties and evaluated MPDA-PEG-CLT's efficacy in synergistic drug-photothermal therapy for osteosarcoma through in vitro and in vivo experiments.
MPDA-PEG-CLT achieved a drug loading capacity of ~14% and a photothermal conversion efficiency of 37.6% under 808 nm NIR irradiation, which enhanced celastrol release. The system induced osteosarcoma cell apoptosis, promoted bone marrow mesenchymal stem cell (BMSC) differentiation, and ameliorated the lesion microenvironment, resulting in efficient tumor ablation in mice.
MPDA-PEG-CLT significantly enhances celastrol's targeted delivery efficiency, promotes mitochondrial apoptosis in osteosarcoma cells, synergizes with photothermal therapy to eradicate tumors, and improves the bone tissue microenvironment in lesions. This system offers a promising strategy for post-surgical osteosarcoma treatment and repair.
MEMBER ACCOUNT
登录成功会直接打开下一页。